Capstone Partners advised MenoLabs, a women’s wellness brand, on its acquisition by Amyris, a publicly traded synthetic biotechnology company. Terms of the deal were not disclosed.
Founded in 2019, MenoLabs is a rapidly growing women’s wellness brand focused on addressing perimenopause and menopause symptoms. MenoLabs is one of few companies offering research-backed, all-natural treatments of menopause symptoms and generates a subscription-based, recurring revenue stream via its website and Amazon Subscribe & Save—all while further expanding its omnichannel by penetrating retail channels in 2022. Over the past two years, the company has developed and launched eight products, including its lead product, MenoFit—an all-natural menopause relief supplement. Additionally, the company launched MenoLife, a highly rated perimenopause and menopause health tracker app, which helps users track and analyze more than 40 menopause-related symptoms and allows them to comment and react to posts in an online forum.
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company’s proprietary Lab-to-Market™ operating platform. The platform leverages state-of-the-art machine learning, robotics, and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world’s top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective, and accessible products.
The acquisition of MenoLabs is expected to accelerate Amyris’ position in the fast-growing menopause market. The companies have synergies through shared formulations, proprietary sector knowledge, existing customer bases, and MenoLife app data that can be leveraged. The transaction has set Amyris to be a leader in the menopause treatment market.
Vanessa Ford, Co-Founder, MenoLabs, said
"We knew we wanted to work with Capstone from the first day we contemplated selling. The team delivered the level of expertise, support, and buyer connections we needed to successfully find the right partner to acquire MenoLabs and bring that deal across the finish line. As 20-year veteran entrepreneurs, our team moves at a very fast pace. Capstone matched us stride for stride and did not let anything fall through the cracks."